More recently, Passeri et al. [96] demonstrated that human DCIL10/glia, generated by genetic engineering of monocytes with lentiviral vectors co-encoding for immunodominant gliadin-derived peptides and IL-10, inhibit pathogenic gliadin-specific CD4+ T cells and promote the differentiation of gliadin-specific Tr1 cells (Figure 2a) in PBMCs from HLA-DQ2+ CeD patients [96]. The gene discussed is CD4; the disease is cranioectodermal dysplasia.